8-K: Yield10 Bioscience Special Meeting Adjourned Due to Insufficient Votes for Asset Sale

Yield10 Bioscience's special meeting to approve the sale of assets to Nuseed and company dissolution was adjourned due to a lack of sufficient shareholder votes, with a reconvened meeting scheduled for November 21, 2024.

Summary

• Yield10 Bioscience held a special meeting on November 8, 2024, to vote on the sale of substantially all assets to Nuseed Nutritional US Inc. and the subsequent liquidation of the company.
• The meeting was adjourned without conducting any business because the required number of votes to approve the asset sale and dissolution proposals were not obtained.
• The special meeting will reconvene on November 21, 2024, to allow additional time for shareholders to vote.
• Approximately 59.9% of outstanding shares had submitted proxies at the time of adjournment.
• Management believes the asset sale to Nuseed is the best option for shareholders to receive any payment for their shares, as they are unlikely to receive any payment in the eventual dissolution if the deal fails.
• A $3 million promissory note to Nuseed was amended such that if the asset sale is not approved by December 2, 2024, the note will become immediately due and payable.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the adjournment of the special meeting, the risk of default on the promissory note, and the potential for no return to shareholders. The company is in a precarious position.

Positives

• Management is actively seeking shareholder approval for the asset sale, which they believe is the best option for shareholders.
• The company is providing additional time for shareholders to vote, indicating a commitment to the process.

Negatives

• The special meeting was adjourned due to a lack of sufficient votes, indicating shareholder uncertainty or opposition.
• The $3 million promissory note to Nuseed is at risk of being called due if the asset sale is not approved by December 2, 2024.
• Failure to complete the asset sale makes it unlikely that shareholders will receive any payment in the eventual dissolution of the company.

Risks

• The company may not secure enough votes to approve the asset sale to Nuseed.
• Failure to approve the asset sale will likely result in no payment to shareholders during dissolution.
• The $3 million promissory note to Nuseed could become immediately due if the asset sale is not approved by December 2, 2024.
• The company may incur additional costs if the special meeting needs to be adjourned again.

Future Outlook

The company is focused on securing shareholder approval for the asset sale to Nuseed, which they believe is the best option for shareholders to receive any payment. Failure to do so will likely result in no payment to shareholders during dissolution.

Management Comments

• Management believes that approval of the Asset Sale Proposal and consummation of the transaction with Nuseed is the best alternative for stockholders of the Company to receive any consideration for their shares.
• Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 commented, 'We continue to strongly encourage all Yield10 stockholders eligible to vote to review the proxy materials and participate in voting, as the proposed asset sale to Nuseed is the only avenue under which stockholders would potentially receive a payment for their shares.'

Industry Context

The document indicates a potential acquisition of Yield10 by Nuseed, which is a common occurrence in the agricultural bioscience industry where smaller companies with promising technologies are often acquired by larger players. This is a sign of consolidation in the industry.

Comparison to Industry Standards

• The situation is similar to other biotech companies that have struggled to achieve profitability and have been acquired by larger companies.
• The use of a promissory note as a bridge loan during acquisition negotiations is a common practice in the industry.
• The potential for a complete liquidation of the company if the acquisition fails is not uncommon for companies in this sector that are unable to secure further funding.

Related Party Transactions

• The promissory note and asset purchase agreement with Nuseed are related party transactions.

Stakeholder Impact

• Shareholders are at risk of not receiving any payment for their shares if the asset sale is not approved.
• Employees may be impacted by the potential sale of assets and dissolution of the company.
• Creditors may be impacted by the potential liquidation of the company.

Next Steps

• The company will reconvene the Special Meeting on November 21, 2024.
• The company will continue to solicit votes from stockholders.
• Shareholders are urged to vote on the proposals as soon as possible.

Key Dates

Keywords

Asset Sale, Dissolution, Shareholder Vote, Promissory Note, Nuseed, Special Meeting, Liquidation, Yield10 Bioscience